Phase 3 trial results demonstrate that bepirovirsen significantly increases the proportion of patients achieving functional cure compared with placebo.

Overall, TherVacB was found to be safe, well-tolerated, and highly immunogenic among the healthy study participants.

Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer Association of Chronic Hepatitis B Infection and ...

Chronic hepatitis B (CHB) affects more than 254 million people globally, with 1.2 million new infections occurring each year. 1 And while it has the potential to cause severe long-term liver problems ...

CHB Fall 2024 ready-to-wear runway, fashion show & collection photos. Designed by CHB at Milan Fashion Week, February 2024.